/4599.T
4599.T Stock - StemRIM
Healthcare|BiotechnologyJPX
$259.00-3.00%
$8.00 (-3.00%) • Dec 24
57
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.20
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.85
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $284.90
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for 4599.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$256.41 – $261.59
TARGET (TP)$297.85
STOP LOSS$238.28
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.86
52W High$370.00
52W Low$246.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $2.35B | $22.98M | $1.40B |
| Gross Profit | $-49,496,000 | $-44,349,000 | $2.35B | $22.98M | $1.40B |
| Gross Margin | N/A | N/A | 100.0% | 100.0% | 100.0% |
| Operating Income | $-1,971,532,000 | $-2,076,000,000 | $142.39M | $-1,980,687,000 | $-593,729,000 |
| Net Income | $-1,929,437,000 | $-2,022,000,000 | $168.35M | $-1,948,306,000 | $-582,447,000 |
| Net Margin | N/A | N/A | 7.2% | -8479.7% | -41.6% |
| EPS | $-31.16 | $-32.98 | $2.80 | $-32.92 | $-10.02 |
Company Overview
StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
4599.TBeat Rate
100%
Last 1 quarters
Avg Surprise
+217.1%
EPS vs Estimate
Beats / Misses
1/0
Last 12 quarters
Latest EPS
$-8.49
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 10, 2026 | — | — | — | — |
Q4 2025 | Dec 10, 2025 | — | $-8.49 | — | — |
Q3 2025 | Sep 10, 2025 | — | $-7.40 | — | — |
Q2 2025 | Jun 11, 2025 | — | $-6.77 | — | — |
Q1 2025 | Mar 11, 2025 | — | $-7.86 | — | — |
Q4 2024 | Dec 11, 2024 | — | $-9.11 | — | — |
Q3 2024 | Sep 11, 2024 | — | $-8.18 | — | — |
Q2 2024 | Jun 12, 2024 | — | $-8.35 | — | — |
Q1 2024 | Mar 13, 2024 | — | $-8.79 | — | — |
Q4 2023 | Dec 13, 2023 | — | $-7.66 | — | — |
Q3 2023 | Sep 13, 2023 | — | $-10.07 | — | — |
Q2 2023 | Jun 14, 2023 | $-25.20 | $29.52 | +217.1% | ✓ BEAT |
Q1 2023 | Mar 8, 2023 | — | $-8.41 | — | — |
Q4 2022 | Dec 14, 2022 | — | $-8.62 | — | — |
Q3 2022 | Sep 8, 2022 | — | $-7.54 | — | — |
Q2 2022 | Jun 9, 2022 | — | $-8.36 | — | — |
Q1 2022 | Mar 10, 2022 | — | $-8.78 | — | — |
Q4 2021 | Dec 9, 2021 | — | $-8.32 | — | — |
Q3 2021 | Sep 9, 2021 | — | $12.10 | — | — |
Q3 2021 | Jul 31, 2021 | — | $-9.08 | — | — |
Latest News
Loading news...
Frequently Asked Questions about 4599.T
What is 4599.T's current stock price?
StemRIM (4599.T) is currently trading at $259.00 per share. The stock has moved -3.00% today.
What is the analyst price target for 4599.T?
No analyst price targets are currently available for this stock.
What sector is StemRIM in?
StemRIM operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the JPX exchange.
What is 4599.T's market cap?
StemRIM has a market capitalization of $16.09 billion, making it a large-cap company.
Does 4599.T pay dividends?
No, StemRIM does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare Sector3902.T
Medical Data Vision Co., Ltd.
$1686.00
Mkt Cap: $63.8B
4538.T
Fuso Pharmaceutical Industries,Ltd.
$2335.00
Mkt Cap: $19.9B
4575.T
CanBas Co., Ltd.
$801.00
Mkt Cap: $15.8B
4579.T
RaQualia Pharma Inc.
$965.00
Mkt Cap: $23.6B
4588.T
Oncolys BioPharma Inc.
$903.00
Mkt Cap: $22.4B
4875.T
MediciNova, Inc.
$210.00
Mkt Cap: $10.3B
4978.T
ReproCELL Incorporated
$141.00
Mkt Cap: $13.4B
7774.T
Japan Tissue Engineering Co., Ltd.
$486.00
Mkt Cap: $19.7B
7776.T
CellSeed Inc.
$234.00
Mkt Cap: $8.1B
8095.T
Astena Holdings Co., Ltd.
$486.00
Mkt Cap: $19.6B
Explore stocks similar to 4599.T for comparison